Saudi Arabia Oncology Clinical Trials Market Report 2022 to 2030

Saudi Arabia Oncology Clinical Trials Market Analysis

$ 3999

Saudi Arabia's Oncology Clinical Trials Market is projected to grow from $215.1 Mn in 2022 to $369.5 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the need for improved cancer treatment alternatives and the rise in collaborations between Saudi Arabian research institutes and foreign organizations. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Tabuk Pharmaceuticals.

ID: IN10SACT006 CATEGORY: Clinical Trials GEOGRAPHY: Saudi Arabia AUTHOR: Vidhi Upadhyay

Buy Now

Saudi Arabia Oncology Clinical Trials Market Executive Summary

The Saudi Arabia Oncology Clinical Trials Market is projected to grow from $215.1 Mn in 2022 to $369.5 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. Saudi Arabia has a robust healthcare system, with standards comparable to those seen in other industrialized nations across the globe. In Saudi Arabia, the ASIR for all forms of cancer is 88.7 per 100,000 people, whereas the age-standardized mortality rate (ASMR) is 43.3 per 100,000 people. According to Globocan's (2020) study, Saudi Arabia had the greatest number of new cancer cases and fatalities attributable to oesophageal cancer in males in the gulf areas.

Research examining the effectiveness and safety of a combination treatment for advanced non-small cell lung cancer (NSCLC) is one example of an ongoing oncology clinical trial in Saudi Arabia. The trial is attempting to improve treatment results for people with advanced NSCLC by combining a particular targeted medication with chemotherapy. Another research investigating a novel immunotherapy medication for the treatment of metastatic breast cancer is another ongoing clinical trial in Saudi Arabia. The medicine works by stimulating the immune system to attack cancer cells, and the study is evaluating its safety and efficacy in patients with metastatic breast cancer who have not responded to traditional therapy.

In addition to these specific examples, there are a number of other ongoing clinical trials in Saudi Arabia related to cancer treatment, including studies focused on improving cancer screening and early detection, evaluating new targeted therapies for a variety of cancer types, and investigating the use of alternative treatment modalities such as herbal medicine. The Saudi Arabian oncology clinical trials landscape demonstrates a priority for developing cancer care and improving patient outcomes, with an emphasis on evaluating novel medicines and enhancing current medications.

saudi arabia oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Many factors have contributed to the increase in oncology clinical trials in Saudi Arabia. To begin with, the nation has a vast and expanding population, with a major section of the population at risk for cancer. This boosts the need for improved cancer treatment alternatives, and clinical trials provide a platform for testing novel and innovative medicines. The Saudi kingdom has committed to improving healthcare infrastructure, including the growth of research and clinical trial skills. This has resulted in a rise in clinical trial financing and resources, as well as the formation of collaborations between Saudi Arabian research institutes and foreign organizations. The Saudi people, as well as healthcare practitioners, are becoming more aware of and accepting of clinical trials. As a result, patient enrolment for clinical trials has grown, as has cooperation between healthcare practitioners and research organizations.

Market Restraints

There are certain constraints that may limit the expansion of oncology clinical trials in Saudi Arabia. One of the most significant challenges is a shortage of skilled professionals, such as clinical research coordinators and data managers, which might hinder research institutes' capacity to perform clinical trials effectively. Another challenge is the scarcity of some pharmaceuticals and therapies in Saudi Arabia, which limits the sorts of studies that may be undertaken. Also, cultural or religious hurdles to participation in clinical trials, especially for women, may exist, limiting the patient population's variety.

Competitive Landscape

Key Players

Pfizer Inc.
Roche Holding AG
Novartis International AG
AstraZeneca plc
Merck & Co., Inc.
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company
Tabuk Pharmaceuticals (SAU)
SPIMACO (SAU)

Notable Insights

In October 2022, Researchers from Saudi Arabia's King Abdullah University of Science and Technology discovered new information on the protein UHRF1, which is one of the most powerful targets for cancer therapy
July 2021, OncoDNA, Tamkin Al-Seha Medical, and Bayer Saudi Arabia have launched a new collaboration to provide access to Neurotrophic Tyrosine Receptor Kinase (NTRK) biomarker testing and identify patients suitable for TRK inhibitor therapy in the Kingdom of Saudi Arabia

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.